Orca Pharmaceuticals GDPR Commitment Statement

The General Data Protection Regulation (GDPR) is the latest EU data privacy and protection framework, which is effective from 25th May 2018.

Orca Pharmaceuticals Ltd is a company based in Oxford UK developing oral drugs for the treatment of chronic inflammatory disease. Whilst we process very little Personal Data, we are committed to ensuring that it is collected, processed, stored and disposed of in line with GDPR standards.

We are committed to GDPR compliance including building GDPR into our current and future processes and contractual commitments.

Dr. Dan R. Littman, Founder of Orca Pharmaceuticals, Honored with Vilcek Prize in Biomedical Science

Dr. Littman received the 2016 Vilcek Prize for his extraordinary achievements in immunology research, specifically, his contributions to insights on HIV pathogenesis, the specificity of the human immune response, and the interplay of the immune system with the human microbiome. The Vilcek Foundation works to raise awareness of immigrant contributions to American society through biomedical research. Dr. Littman serves as a Professor of Pathology and Microbiology at the Skirball Institute of Biomolecular Medicine of New York University School of Medicine.  Orca Pharmaceuticals (www.orcapharmaceuticals.com) is based on his discoveries.

Click here for more

Orca Pharmaceuticals Partners Topical RORy Inhibitors with Brickell Biotech for Dermatology Development

Orca Pharmaceuticals has entered into a transaction with Brickell Biotech, a clinical-stage pharmaceutical company focused on the development of dermalotology therapeutics, in which Brickell will assume the responsibility for the continued development of these RORy inhibitors.

“We are excited about this new agreement with Orca Pharmaceuticals and look forward to having the opportunity to develop a topically applied, potent and selective small-molecule therapeutic for psoriasis,” said Patricia Walker, M.D., Ph.D., President and Chief Scientific Officer of Brickell Biotech.

Dr Michael Hunter, CEO of Orca Pharmaceuticals commented, “We are delighted to partner this program with Brickell Biotech. Brickell's deep knowledge of dermatological development will be invaluable in bringing these much needed treatments to patients".

Click here for more

Orca Pharmaceuticals and AstraZeneca Announce Development Partnership

Orca Pharmaceuticals and AstraZeneca announced a partnership to develop inhibitors against a wide range of autoimmune diseases. Orca will receive upfront and milestone payments from AstraZeneca with a potential total value of $122.5 million.

Click here for more

Orca Pharmaceuticals Achieves Development Milestone and Secures Additional Funding

Orca Pharmaceuticals, a biotechnology start-up developing RORgamma inhibitors for the treatment of autoimmune diseases, has announced a further investment of $1.3 million from BioMotiv, a drug development accelerator based in Cleveland, Ohio and affiliated with The Harrington Project.

Click here for more

BioMotiv and New York University join forces to form Orca Pharmaceuticals, a new autoimmune disease company

Orca Pharmaceuticals, a new biotechnology start-up focused on treating autoimmune diseases, has today announced its formation. Funding is from BioMotiv, a Cleveland, Ohio based therapeutics accelerator affiliated with The Harrington Project, and the New York University Innovation Venture Fund. The company, located in Oxford UK, is based on technology developed by inventors from New York University (NYU) in collaboration with the founders in the United Kingdom.

Click here for more